STABILIZATION OF RADIOSYNTHETIC INTERMEDIATES

专利摘要:
STABILIZATION OF RADIOSYNTHETIC INTERMEDIARIES The present invention relates to a method for the stabilization of radiosynthetic intermediates used in the synthesis of aromatic amino acid derivatives radiolabeled with 18F against the decomposition caused by beta and gamma radiation, by the use of scavengers of radicals or reducing agents or antioxidants.
公开号:BE1021078B1
申请号:E2014/0196
申请日:2014-03-21
公开日:2015-04-21
发明作者:Muhammad Otabashi；Gauthier Philippart；Samuel Voccia；Ludovic Wouters；Jean-Luc Morelle
申请人:Trasis S.A.；
IPC主号:

专利说明:

STABILIZATION OF RADIOSYNTHETIC INTERMEDIATES OBJECT OF THE INVENTION
The present invention relates to processes for the synthesis of aromatic amino acids radiolabeled with 18F and in particular a method for the stabilization of radiosynthetic intermediates used in said methods with respect to their decomposition caused by beta and gamma radiation. STATE-OF-THE-ART Positron Emission Tomography [0002] Positron Emission Tomography (PET) is an imaging method for obtaining quantitative information of physiological processes in the body at the molecular and biochemical level. The most widely used PET radiotracer today is [18F] - fluorodeoxyglucose ([18F] -FDG), a radiolabeled glucose molecule. [18F] -FDG PET imaging visualizes glucose metabolism and has a wide range of clinical indications. Among the emitters of positions, the 18F is the most widely used today in the clinical environment. Decomposition of radiopharmaceutical products - radiolysis [0003] Radiotracers are obtained after a single or multi-stage organic synthesis step, including fluorination with 18F fluorides. Radiosynthetic intermediates are generally involved in these radiosyntheses. These radiosynthetic intermediates may be exposed to high levels of radioactivity and high dose rates that may result in the onset of decomposition processes commonly referred to as radiolysis. These side reactions can consume these radiosynthetic intermediates or generate reactions with 18F fluorides and are detrimental to obtaining high radiochemical yields.
The modes by which radiosynthetic intermediates decompose and the corresponding control methods were classified in 1960 (Bayly, RJ and Weigel, H., Self-decomposition of compounds labeled with radioactive isotopes, Nature, 188, 384-387 (1960). ) (see Table I below).
Table I (Bavlv, R.J. and Weigel, H. extract, Self-decomposition of compounds labeled with radioactive isotopes). Nature. 188, 384-387 (1960) [0004] The compound itself and / or its immediate environment will absorb the energy of the radiation. This energy excites molecules, which can split or react with other species or compounds. The excited molecular species can also react with other labeled compounds and cause the production of impurities. The energy absorbed by the immediate environment (mainly the solvent) can also produce reactive species, such as free radicals, which can then cause the destruction of the radiolabelled compound molecules. Although these radiolysis decompositions occur in solids, these chemical decomposition reactions are exacerbated in a solution where chemical stability is known to be much more limited. Secondary Decomposition [0005] This is usually the main cause of decomposition of radiochemicals and this results from the interaction, for example, of free radicals created by radiation energy, with surrounding molecules, including radiolabeled molecules. This mode of decomposition is by far the most difficult mode to control and is easily influenced by tiny changes in environmental conditions. The low content in the medium of these radiolabelled compounds, in particular with high specific activity, amplifies the problems. Secondary Decomposition in Water Solutions [0006] The action of ionizing radiation on water is well documented (Thomas, JK, Elementary processes and reactions in the radiolysis of water, Advances in Radiation Chemistry, 1, 103-198 ( 1969)). Ionization is known to occur along the path of beta particles in distinct compartments called "spurs" (Collison, E. and Avale, AJ, The action of ionizing radiation on organic compounds. 311-327 (1955)). The most damaging reactive species that can be formed is the hydroxyl radical (Evans, E.A., Tritium and its compounds, 2nd edition, Butterworths, London, pp. 642-782 (1974)). This has been demonstrated by the hydroxylation reaction of carbon-14 or tritium-labeled phenylalanine derivatives, tyrosine and dihydroxyphenylalanine (Waldeck, B., [3H] Dopa in [3H] tyrosine with high specific activity Journal of Pharmacy and Pharmacology, 23, 64-65 (1971)). In order to reduce decomposition, it is necessary to avoid or reduce interactions between harmful radicals and surrounding molecules, including radiolabelled molecules. This can be achieved by lowering the temperature, dilution of the radioactivity concentration, and adding radical scavengers. Ethanol is for example a common radical scavenger (typically as a 2% solution in water). . Secondary Decomposition in Organic Solvents [0007] The detailed mechanism of the decomposition of radioactive compounds in organic solvents is not well known and is expected to be complex. The effect of radiation energy on organic solvents is able, unlike in the water, to produce different forms of reactive species. The chemical purity of the solvent is certainly a critical parameter, so the solvents used should be well purified or of very high quality. The presence of peroxide in the solution can cause total destruction of nearby molecules, including radiolabelled molecules.
[18F] Radiolabeled aromatic amino acid derivatives Radiolabeled aromatic amino acid derivatives such as 18F-FDOPA, 18F-FTYR, 18F-FmTYR, etc. are often used to control the metabolism in the dopaminergic system. These radiotracers may be indicated for imaging Parkinson's disease (PD), Alzheimer's disease (AD) and certain neurodegenerative diseases. These radiotracers have also attracted interest in medical imaging of neuroendocrine tumors (NET).
Radiolabelled aromatic amino acid derivatives can be synthesized according to different methods or paths such as, for example: Lemaire et al.
- Di Magno et al.
R = H, 4-Me, 2-OMe, 3-OMe, 4-OBn, 4-1, 4-Br, 4-Cl X = Br, OTs, OTf-Coenen et al.
- Mulholland et al.
- Ritter et al.
- Electrophilic synthesis from 18F2
However, most of these syntheses show a fall in radiochemical yields at high level of radioactivity due to the instability of the benzyl species and / or phenolics in the presence.
PROBLEM TO SOLVE
Benzylic and Phenolic Radiosynthetic Intermediates The instability with regard to radioactivity and in particular beta and gamma radiation can be attributed to the presence of the aromatic ring (see above reactivity towards hydroxyl radicals), but also to the presence of benzyl or phenolic groups, whatever the synthesis route chosen for the synthesis of radiolabelled aromatic amino acids (see above).
These reaction positions may be subject to side reactions that will consume radiosynthetic intermediates, including cold intermediates such as the precursor used for labeling, which will no longer be available for the subsequent stages of radiosynthesis. This is consistently detrimental to obtaining high radiosynthetic yields, particularly in radiopharmacies where the starting activity is in the range of 1-30Ci, i.e. 15Ci / ml.
WO 2005/061415 A1 describes the preparation of a resin bearing benzyl groups (Example 13). This resin is used as an intermediate in the synthesis of 18F-FDOPA (Example 11). 2,2,6,6-tetramethylpiperidin-1-yl) oxidanyl (TEMPO) is used as a stabilizing agent. In this context, ascorbate is also known to be a free radical trap.
PURPOSE OF THE INVENTION
The present invention aims to avoid the decomposition reactions of radiosynthetic intermediates used in the synthesis of 18F-labeled aromatic amino acids (radiolysis resulting from high concentrations of radioactivity), by the use of scavengers of radicals or reducing agents or antioxidants during the crucial stages of radiosynthesis. In other words, the invention aims to stabilize the aromatic radiochemical yields of aromatic amino acids, regardless of the level of starting radioactivity used.
DESCRIPTION OF THE INVENTION
The present invention relates to the stabilization with respect to radiolysis of radiosynthetic intermediates, including cold intermediates such as the precursor used for labeling, by the use of radical scavengers or reducing agents or antioxidants during the stages where high concentrations of radioactivity are involved. The decomposition is exacerbated in the presence of water, by the formation of very reactive hydroxyl radicals which break down these intermediates.
The present invention focuses on the radiosynthetic intermediates involved in the synthesis of 18F-labeled aromatic amino acids, including cold molecules such as the precursor to radiolabel, due to the instability of the aromatic ring and benzyl species. and phenolic involved in these syntheses.
The general structure of these intermediate products to be stabilized in the context of the present invention is presented below:
with R1, R3, R4, Rs and L as follows: R1 R2, R3 R4 = OMe, OBn, Oallyl, H, OH:
* L = NO2, NMe3 +, F, 18F; and * R5 = OH, I, Br, Cl
Because of the side reactions that occur during the decomposition of intermediate products, the "stabilizer" used during the radiosynthesis process can be either: - a scavenger radicals; a reducing agent; an antioxidant; - a species with at least two of the above characteristics. According to the present invention, an iodide is used as a stabilizing agent for the radiosynthetic intermediate. In certain preferred embodiments of the present invention, this iodide is used both for the stabilization of the radiosynthetic intermediate and as a reagent and may be involved in chemical reactions such as halogenation or hydrolysis / deprotection. .
The embodiments below are outside the invention.
In some embodiments, carbonate (CO32 '), nitrite, thiosulfate, thiosulfite, phosphate, phosphite or hypophosphite is used for the stabilization of the radiosynthetic intermediate.
In some embodiments, the phosphorous acid is used for the stabilization of the radiosynthetic intermediate.
In some embodiments, a Fe (II) derivative or a Sn (II) derivative is used for the stabilization of the radiosynthetic intermediate.
In some embodiments, a phenol derivative is used for the stabilization of the radiosynthetic intermediate.
In some embodiments, the compound used for stabilization is also involved in the process of radiosynthesis as a reagent or as a solvent.
In some embodiments, toluene is used as a solvent and for the stabilization of the radiosynthetic intermediate.
In some embodiments, the dichloromethane is used as a solvent and for the stabilization of the radiosynthetic intermediate.
EXAMPLES
In these examples, it has been shown how the good choice of additives and reagents makes it possible to stabilize the yields in the direction of the increase of the starting activity.
Example 1 Synthesis of [18F] FD0PA with the method described by Lemaire et al. and elimination of H1 in the crucial step
R! = NO2; NMe 3 +
H! was used for halogenation and is removed by rinsing with + KOH water during the cartridge halogenation process. It was also used during the deprotection / hydrolysis step.
Low activity (~ 100mCi) EOS yield: 30% (n = 18).
High activity (~ 6Ci) EOS yield: 3% (n = 6).
Example 2 Synthesis of [18F] -FD0PA with the method described by Lemaire et al. and use of Hl for halogenation
Rj = NO2 NMe3 +
H1 has been used for halogenation and remains present throughout the halogenation process on cartridge. It was also used during the deprotection / hydrolysis step. Low activity (~ 100mCi) EOS yield: 25% (n = 20). High activity (~ 6CI) EOS yield: 25% (n = 10).
Example 3 Synthesis of [18F] -FD0PA with the method described by Lemaire et al. and with replacement of Hl with HBr in the crucial step
R1 = N02NMe3 +
HBr was used for halogenation. It was used during the deprotection / hydrolysis step.
Low activity (~ 100mCi) EOS yield: 20% (n = 3).
High activity (~ 3Ci) EOS yield: 12% (n = 2).
Example 4: Synthesis of [18F] -FD0PA with the method described by Lemaire et al. and with replacement of Hl with HBr / KI in the crucial step
R1 = NO2; NMe3 +
HBr was used for halogenation in a mixture with Kl. It was used during the deprotection / hydrolysis step.
Low activity (~ 100mCi) EOS yield: 21% (n = 3).
High activity (~ 3Ci) EOS yield: 19% (n = 2).
Example 5: Synthesis of [18F] FD0PA with the method described by Di Magno et al. and HBr
HBr was used during the deprotection / hydrolysis step.
Low activity (~ 100mCi) EOS yield: 18% (n = 2).
High activity (~ 1.5Ci) EOS yield: 9% (n = 1).
Example 6: Synthesis of [18F] -FDOPA with the method described by Coenen et al. and HBr
HBr was used during the deprotection / hydrolysis step.
Low activity (~ 60mCi) EOS yield: 15% (n = 1).
High activity (~ 3Ci) EOS yield: 8% (n = 1).
Example 7: Synthesis of [18F] -FD0PA with the method described by Coenen et al. and HBr / KI
HBr / Kl was used during the deprotection / hydrolysis step.
Low activity (~ 50mCi) Yield: 12% (n = 1).
High activity (~ 3Ci) Yield: 11% (n = 1).

权利要求:
Claims (2)
[1]
A method of stabilizing a radiosynthetic intermediate used in the synthesis of 18F radiolabeled aromatic amino acids having the general structure:

with R1, R2, R3, R4, R5 and L as follows: R1 R2, R4 R4 = H, OMe, O, N, O, J, H, OH;



* L = NO2, NMe3% F, 18F,; and

• R5 ~ OH. I. Br. CI against the decomposition caused by beta and gamma radiation, comprising a step of using an iodide as a stabilizing agent of the radiosynthetic intermediate.
[2]
The method of claim 1, wherein said iodide is used both for stabilization of the radiosynthetic intermediate and as a reagent.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Forsback et al.2008|Electrophilic synthesis of 6-[18F] fluoro-L-DOPA using post-target produced [18F] F2

---

Li et al.2011|Transformation of the antiepileptic drug oxcarbazepine upon different water disinfection processes

---

Teare et al.2007|Synthesis and reactivity of [18F]-N-fluorobenzenesulfonimide

---

Dheere et al.2013|Rapid and efficient synthesis of [11 C] ureas via the incorporation of [11 C] CO 2 into aliphatic and aromatic amines

---

BE1021078B1|2015-04-21|STABILIZATION OF RADIOSYNTHETIC INTERMEDIATES

---

EP2238139B1|2017-09-27|Method for preparing a marked purine derivative, said derivative and uses thereof

---

Lee et al.2013|Development of a new precursor‐minimizing base control method and its application for the automated synthesis and SPE purification of [18F] fluoromisonidazole |

---

CN1060164C|2001-01-03|N-morpholino-N-nitrosaminoacetonitril cyclodextrin inclusion complexes

---

EP3003399B1|2017-02-01|Novel chemical compounds derived from normemantine and use of same in the medical field

---

FR3054445B1|2019-07-05|SYNTHESIS OF A RADIOACTIVE AGENT COMPOSITION

---

EP3589607B1|2021-05-05|A process for producing flutemetamol

---

Eskola et al.2004|A novel electrophilic synthesis and evaluation of medium specific radioactivity |-4-[18F] fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET

---

EP2516450A1|2012-10-31|Method for preparing thpx

---

JP6842415B2|2021-03-17|How to remove acetaldehyde from radiopharmaceuticals

---

US10695450B2|2020-06-30|Synthesis of a radioactive agent composition

---

KR102167951B1|2020-10-20|Rapid synthesis method by solid-phase extraction of carbon-11 labeled compounds

---

BE1024388B1|2018-02-12|PROCESS FOR THE PREPARATION OF NITROIMIDAZOLE ANALOGS BASED ON RADIO-BASED NUCLEOSIDE

---

US8030526B2|2011-10-04|Simple, rapid method for the preparation of isotopically labeled formaldehyde

---

CA1301195C|1992-05-19|Process for the chloration of phenolic compounds

---

FR2748023A1|1997-10-31|HYDROGENOFLUOROSULFONATES OF ORGANIC BASIS, THEIR USE TO RELEASE ORGANIC BASES FROM THEIR FLUORHYDRATE, THEIR PROCESS FOR PREPARATION, COMPOSITIONS CONTAINING THEM

---

Adam et al.1990|Synthesis of L‐6‐[123I] iodo‐m‐tyrosine a potential spect brain imaging agent

---

Kersemans et al.2011|Mechanistic approach of the difference in hydrolysis rate between the 2‐and 4‐isomers of no‐carrier‐added [18F] fluoromethyl‐L‐phenylalanine

---

Thibaud et al.1986|Formation de chloropicrine lors de la chloration de quelques composes organiques nitres en solution aqueuse. Incidence d'une preozonation. Chloropicrin formation during the chlorination of some organic nitro compounds in aqueous solution. Incidence of a preozonation treatment.

---

Kersemans et al.2011|Mechanistic approach of the difference in non‐enzymatic hydrolysis rate between the L and D enantiomers of no‐carrier added 2‐[18F] fluoromethyl‐phenylalanine

---

US20090260971A1|2009-10-22|Method of preparing fluoroalkyl compounds using radiation

同族专利:

---

公开号 | 公开日

---

WO2014147244A1|2014-09-25|

---

EP2821383A1|2015-01-07|

---

JP6435317B2|2018-12-05|

---

CN105050984B|2019-05-21|

---

IN2015DN08660A|2015-10-16|

---

KR102205673B1|2021-01-22|

---

JP2016517842A|2016-06-20|

---

CN105050984A|2015-11-11|

---

US20160075615A1|2016-03-17|

---

KR20150132829A|2015-11-26|

---

AU2014234260B2|2018-07-26|

---

EP2821383B1|2017-08-30|

---

AU2014234260A1|2015-08-20|

---

US9796641B2|2017-10-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO2005061415A1|2003-12-23|2005-07-07|Ge Healthcare Limited|Radical trap in fluoridation of iodonium salt|

---

JP3165775B2|1994-08-31|2001-05-14|日本鋼管株式会社|Method for producing fluorine radioisotope-labeled L-dopa|

---

DE19949237B4|1999-10-13|2004-07-29|Abx Advanced Biochemical Compounds Biomedizinische Forschungsreagenzien Gmbh|Precursor compound for radio diagnostics and process for their manufacture|

---

WO2002044144A2|2000-11-30|2002-06-06|Advanced Research And Technology Institute, Inc.|Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds|

---

CN1245378C|2002-01-31|2006-03-15|中国科学院上海原子核研究所|Process for preparing 6-[F]fluoro-L-dopa|

---

RU2006105644A|2003-07-24|2006-08-10|Бракко Имэджинг С.П.А. |STABLE RADIO-PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING THEM|

---

DE102007059313A1|2007-12-07|2009-06-18|Forschungszentrum Jülich GmbH|A process for the preparation of precursors for L-3,4-dihydroxy-6- [18F] fluoro-phenylalanine and 2- [18F] fluoro-L-tyrosine and their α-methylated derivatives, precursors, and to processes for producing L-3 , 4-Dihydroxy-6- [18F] fluoro-phenylalanine and 2- [18F] fluoro-L-tyrosine and their α-methylated derivatives from the precursor|

---

GB0814893D0|2008-08-14|2008-09-17|Ge Healthcare Ltd|Improved fluoridation of iodonium salts|CN107311877B|2017-07-21|2019-03-05|王璐|A kind of positron medicine [18F] FDOPA novel processing step and its intermediate|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US201361804371P| true| 2013-03-22|2013-03-22|

---

US61/804371|2013-03-22|

---

EP61/804371|2013-03-22|

---

EP13174707.3A|EP2821383B1|2013-07-02|2013-07-02|Stabilization of radiosynthetic intermediates|

---